Explore PTSD prevalence, comorbidities, and first-line care as we invite clinicians to share cases and research.
|Articles|August 12, 2022
An Update on Neuromodulation
Author(s)Ben Greenberg, MD, PhD
What are some of the most exciting emerging and established methods?
Advertisement
Ben Greenberg, MD, PhD, shares some key takeaways from his presentation on methods of neuromodulation with Dhakshin Ramanathan, MD, PhD, of the University of California, San Diego, at the
Dr Greenberg is director of COBRE Center for Neuromodulation at Butler Hospital.
Advertisement
Related to this article
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
How genes and early stress interact to shape antisocial behavior, from dopamine and serotonin pathways to MAOA and oxytocin findings.
Policy shifts have opened the door to telehealth buprenorphine for pregnant and postpartum women with OUD, but research, guidelines, and state policy lag behind.
Overlooking how hearing loss and sign language shape the Mental Status Examination can make language deprivation look like psychosis, authors warn.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Explore Q3 2026 psych pipeline highlights—wins, setbacks, top disorders, and breakthrough ADHD, TRD, schizophrenia and Alzheimer therapies to watch.
The menopause transition carries a 2-fold increased risk of depression, and an expert explains how clinicians can screen for it, tell it apart from other conditions, and treat it.
Advertisement
Advertisement
Trending on Psychiatric Times
1
September 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
2
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
3
VA Expands Informed Consent Requirements for Psychotropic Medications Starting in 2027
4
The Psychiatric Pipeline in Review: Quarter 3, 2026
5